^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    5d
    Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Koselugo (selumetinib) • Recentin (cediranib)
    5d
    ILLUMINE: Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (clinicaltrials.gov)
    P3, N=780, Not yet recruiting, Groupe Oncologie Radiotherapie Tete et Cou
    Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yidafan (ivonescimab) • ligufalimab (AK117)
    6d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=387, Recruiting, Pfizer
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    9d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=190, Recruiting, Pfizer
    New P3 trial
    |
    Avastin (bevacizumab)
    9d
    A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=345, Recruiting, Pfizer
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    10d
    Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov)
    P3, N=561, Recruiting, AbbVie
    Trial initiation date • Adverse events • Real-world evidence
    |
    Lucentis (ranibizumab)
    13d
    C6461003: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer (2025-523521-18-00)
    P2/3, N=92, Not yet recruiting, Pfizer Inc.
    New P2/3 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    13d
    C6461001: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (2025-523461-17-01)
    P2/3, N=203, Not yet recruiting, Pfizer Inc.
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    14d
    SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    trastuzumab rezetecan (SHR-A1811) • Yidafan (ivonescimab)
    15d
    Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (clinicaltrials.gov)
    P2, N=60, Enrolling by invitation, Sun Yat-sen University
    New P2 trial
    |
    Yidafan (ivonescimab)
    15d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Pfizer
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    18d
    JADE: A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (clinicaltrials.gov)
    P1, N=164, Completed, Ollin Biosciences, Inc.
    New P1 trial